General Information of Drug Transporter (DT)
DT ID	DTD0020 Transporter Info
Gene Name	SLC10A2
Protein Name	Apical sodium-dependent bile acid transporter
Gene ID	6555
UniProt ID	Q12908
Genetic Polymorphisms of DT (GPD)
Genetic Polymorphism	rs2301159
Site of GPD	chr13:103045378 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	G>A
Minor Allele Frequency	A=0.2704/1354 (Global)
Allele A	Click to Show/Hide the Full List of Affected Drugs:           6 Drugs in Total
Docetaxel	Drug Info	Prostatic Neoplasm	Correlated with the increased drug toxicity risk in patients (compare with allele G)		[ 1]
Thalidomide	Drug Info	Prostatic Neoplasm	Correlated with the increased drug toxicity risk in patients (compare with allele G)		[ 1]
Docetaxel	N.A.	Neoplasms	Allele A is associated with increased risk of toxicity when treated with docetaxel and thalidomide in people with Prostatic Neoplasms as compared to allele G.		[ 1]
Thalidomide	N.A.	Neoplasms	Allele A is associated with increased risk of toxicity when treated with docetaxel and thalidomide in people with Prostatic Neoplasms as compared to allele G.		[ 1]
Docetaxel	N.A.	Prostatic Neoplasms	Allele A is associated with increased risk of toxicity when treated with docetaxel and thalidomide in people with Prostatic Neoplasms as compared to allele G.		[ 1]
Thalidomide	N.A.	Prostatic Neoplasms	Allele A is associated with increased risk of toxicity when treated with docetaxel and thalidomide in people with Prostatic Neoplasms as compared to allele G.		[ 1]
Genotype AA	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Docetaxel	N.A.	Prostatic Neoplasms	Patients with the AA genotype may have an increased risk of toxicity with docetaxel and thalidomide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence treatment response.		[ 1]
Thalidomide	N.A.	Prostatic Neoplasms	Patients with the AA genotype may have an increased risk of toxicity with docetaxel and thalidomide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence treatment response.		[ 1]
Genotype AG	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Docetaxel	N.A.	Prostatic Neoplasms	Patients with the AG genotype may have an increased risk of toxicity with docetaxel and thalidomide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence treatment response.		[ 1]
Thalidomide	N.A.	Prostatic Neoplasms	Patients with the AG genotype may have an increased risk of toxicity with docetaxel and thalidomide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence treatment response.		[ 1]
Genotype GG	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Docetaxel	N.A.	Prostatic Neoplasms	Patients with the GG genotype may have decreased but not absent risk of toxicity with docetaxel and thalidomide as compared to patients with the AG or AA genotypes. Other genetic and clinical factors may also influence treatment response.		[ 1]
Thalidomide	N.A.	Prostatic Neoplasms	Patients with the GG genotype may have decreased but not absent risk of toxicity with docetaxel and thalidomide as compared to patients with the AG or AA genotypes. Other genetic and clinical factors may also influence treatment response.		[ 1]
Genetic Polymorphism	rs7319981
Site of GPD	chr13:103071372 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	G>A
Minor Allele Frequency	A=0.3790/1898 (Global)
Allele A	Click to Show/Hide the Full List of Affected Drugs:           9 Drugs in Total
Daunorubicin	Drug Info	Neoplasm	Irrelevant to the likelihood of cardiotoxicity in patients (compare with Allele G)		[ 2]
Doxorubicin	Drug Info	Neoplasm	Irrelevant to the likelihood of cardiotoxicity in patients (compare with Allele G)		[ 2]
Anthracyclines And Related Substances	N.A.	Neoplasms	Allele A is associated with decreased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to allele G.		[ 3]
Anthracyclines And Related Substances	N.A.	Cardiotoxicity	Allele A is associated with increased risk of Cardiotoxicity when exposed to anthracyclines and related substances in people with Hodgkin Disease or Sarcoma as compared to allele G.		[ 4]
Daunorubicin	N.A.	Cardiotoxicity	Allele A is not associated with likelihood of cardiotoxicity when exposed to daunorubicin and doxorubicin in children with Neoplasms as compared to allele G.		[ 2]
Doxorubicin	N.A.	Cardiotoxicity	Allele A is not associated with likelihood of cardiotoxicity when exposed to daunorubicin and doxorubicin in children with Neoplasms as compared to allele G.		[ 2]
Anthracyclines And Related Substances	N.A.	Neoplasms	Allele A is associated with decreased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to allele G.		[ 3]
Anthracyclines And Related Substances	N.A.	Neoplasms	Allele A is not associated with likelihood of cardiotoxicity when exposed to daunorubicin and doxorubicin in children with Neoplasms as compared to allele G.		[ 2]
Anthracyclines	N.A.	Neoplasm	Correlated with the decreased likelihood of cardiotoxicity in patients (compare with allele C)		[ 3]
Genotype AA	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Anthracyclines And Related Substances	N.A.	Neoplasms	Patients with the AA genotype may have decreased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype GG, although this is contradicted in one study. Other genetic and clinical factors may also influence the toxicity to anthracyclines.		[ 3]
Genotype AG	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Anthracyclines And Related Substances	N.A.	Neoplasms	Patients with the AG genotype may have decreased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype GG, although this is contradicted in one study. Other genetic and clinical factors may also influence the toxicity to anthracyclines.		[ 3]
Genotype GG	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Anthracyclines And Related Substances	N.A.	Neoplasms	Patients with the GG genotype may have increased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype AA or AG, although this is contradicted in one study. Other genetic and clinical factors may also influence the toxicity to anthracyclines.		[ 3]
Genetic Polymorphism	rs9514091
Site of GPD	chr13:103061904 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	G>A
Minor Allele Frequency	A=0.2346/1175 (Global)
Allele A	Click to Show/Hide the Full List of Affected Drugs:           8 Drugs in Total
Daunorubicin	Drug Info	Neoplasm	Irrelevant to the likelihood of cardiotoxicity in patients (compare with Allele G)		[ 2]
Doxorubicin	Drug Info	Neoplasm	Irrelevant to the likelihood of cardiotoxicity in patients (compare with Allele G)		[ 2]
Anthracyclines And Related Substances	N.A.	Neoplasms	Allele A is associated with decreased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to allele G.		[ 3]
Daunorubicin	N.A.	Cardiotoxicity	Allele A is not associated with likelihood of cardiotoxicity when exposed to daunorubicin and doxorubicin in children with Neoplasms as compared to allele G.		[ 2]
Doxorubicin	N.A.	Cardiotoxicity	Allele A is not associated with likelihood of cardiotoxicity when exposed to daunorubicin and doxorubicin in children with Neoplasms as compared to allele G.		[ 2]
Anthracyclines And Related Substances	N.A.	Neoplasms	Allele A is associated with decreased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to allele G.		[ 3]
Anthracyclines And Related Substances	N.A.	Neoplasms	Allele A is not associated with likelihood of cardiotoxicity when exposed to daunorubicin and doxorubicin in children with Neoplasms as compared to allele G.		[ 2]
Anthracyclines	N.A.	Neoplasm	Correlated with the decreased likelihood of cardiotoxicity in patients (compare with allele C)		[ 3]
Genotype AA	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Anthracyclines And Related Substances	N.A.	Neoplasms	Patients with the AA genotype may have decreased but not absent risk for cardiotoxicity when exposed to anthracyclines for pediatric cancer as compared to patients with the GG genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence risk for cardiotoxicity.		[ 3]
Genotype AG	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Anthracyclines And Related Substances	N.A.	Neoplasms	Patients with the AG genotype may have decreased but not absent risk for cardiotoxicity when exposed to anthracyclines for pediatric cancer as compared to patients with the GG genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence risk for cardiotoxicity.		[ 3]
Genotype GG	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Anthracyclines And Related Substances	N.A.	Neoplasms	Patients with the GG genotype may have an increased risk for cardiotoxicity when exposed to anthracyclines for pediatric cancer as compared to patients with the AA or AG genotypes, although this is contradicted in one study. Other genetic and clinical factors may also influence risk for cardiotoxicity.		[ 3]
References
1	A pharmacogenetic study of docetaxel and thalidomide in patients with castration-resistant prostate cancer using the DMET genotyping platform. Pharmacogenomics J. 2010 Jun;10(3):191-9.
2	Validation of variants in SLC28A3 and UGT1A6 as genetic markers predictive of anthracycline-induced cardiotoxicity in children. Pediatr Blood Cancer. 2013 Aug;60(8):1375-81.
3	Pharmacogenomic prediction of anthracycline-induced cardiotoxicity in children. J Clin Oncol. 2012 May 1;30(13):1422-8.
4	Risk of anthracycline-induced cardiac dysfunction in adolescent and young adult (AYA) cancer survivors: role of genetic susceptibility loci. Pharmacogenomics J. 2024 Jun 29;24(4):21.

If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.